Literature DB >> 15136636

99mTc-labeled antimicrobial peptide ubiquicidin (29-41) accumulates less in Escherichia coli infection than in Staphlococcus aureus infection.

Muhammad Saeed Akhtar1, Javed Iqbal, Muhammad Aleem Khan, Javaid Irfanullah, Mustansar Jehangir, Bashar Khan, Ikram Ul-Haq, Ghulam Muhammad, Muhammad Afzal Nadeem, Muhammad Shehzad Afzal, Muhammad Babar Imran.   

Abstract

UNLABELLED: 99mTc-Labeled antimicrobial peptide ubiquicidin, (99m)Tc-UBI (29-41) in a freeze-dried kit, was evaluated as a bacterial infection-seeking agent in Staphlococcus aureus- and Escherichia coli-induced infections.
METHODS: Thirty-three rabbits were classified in 3 groups. Biodistribution of (99m)Tc-UBI (29-41) was studied in 3 animals (group I). Uptake of peptide was determined by counting radioactivity in anatomically fitted regions drawn over the liver, kidneys, urinary bladder, and whole body and expressed as the percentage uptake per organ. Experimental thigh muscle infection was induced by injecting 2 x 10(8) colony-forming units of live S. aureus or E. coli bacteria into the right thigh muscle in 20 rabbits (group II). Turpentine oil and formalin-killed S. aureus were used for inducing sterile thigh muscle inflammation in 10 rabbits (group III). On scintigrams, anatomically adjusted regions of interest were drawn over infected/inflamed (target) and noninfected/noninflamed (nontarget) thigh, and accumulation of (99m)Tc-UBI (29-41) at sites of infection/inflammation was expressed as a target-to-nontarget (T/NT) ratio.
RESULTS: A biodistribution study of (99m)Tc-UBI (29-41) revealed rapid removal of tracer from the circulation via the kidneys (10.6% +/- 2.1% at 5 min and 5.9% +/- 0.8% at 60 min) with accumulation of the major part in the urinary bladder within the first hour after injection (66.6% +/- 7.2%). A significantly higher (P < 0.05) accumulation of (99m)Tc-UBI (29-41) was seen at sites of S. aureus-infected animals (T/NT ratio, 2.2 +/- 0.5) compared with that of E. coli-infected animals (T/NT ratio, 1.7 +/- 0.4). The maximum tracer accumulation was observed at 60 min after injection followed by a gradual decline. No significant accumulation was noticed in thighs of rabbits injected with either turpentine oil or killed S. aureus with markedly lower T/NT ratios (P < 0.05) compared with that of S. aureus- and E. coli-infected thighs.
CONCLUSION: A (99m)Tc-UBI (29-41) freeze-dried kit can be used for differentiating infections with S. aureus and E. coli with significantly higher scintigraphic intensity (P < 0.05) compared with that of sterile inflammatory sites. The optimum time for infection imaging is 60 min after injection. Relatively low (T/NT) ratios were observed in E. coli infections compared with those of the S. aureus group, which may be due to a low virulence of the former; however, other possible reasons may include low affinity of this peptide for E. coli microbial membranes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136636

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

1.  Optical imaging of bacterial infection in living mice using deep-red fluorescent squaraine rotaxane probes.

Authors:  Alexander G White; Na Fu; W Matthew Leevy; Jung-Jae Lee; Michael A Blasco; Bradley D Smith
Journal:  Bioconjug Chem       Date:  2010-07-21       Impact factor: 4.774

2.  Evaluation of [¹¹¹In]-labeled zinc-dipicolylamine tracers for SPECT imaging of bacterial infection.

Authors:  Douglas R Rice; Adam J Plaunt; Serhan Turkyilmaz; Miles Smith; Yuzhen Wang; Mary Rusckowski; Bradley D Smith
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

3.  Investigation of four (99m)Tc-labeled bacteriophages for infection-specific imaging.

Authors:  Mary Rusckowski; Suresh Gupta; Guozheng Liu; Shuping Dou; Donald J Hnatowich
Journal:  Nucl Med Biol       Date:  2008-05       Impact factor: 2.408

4.  Scintigraphic visualization of bacterial translocation in experimental strangulated intestinal obstruction.

Authors:  Yu M Galeev; Yu B Lishmanov; E G Grigorev; M V Popov; K A Aparcin; O V Salato
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-13       Impact factor: 9.236

5.  An imaging analysis of (99m)Tc-UBI (29-41) uptake in S. aureus infected thighs of rabbits on ciprofloxacin treatment.

Authors:  Muhammad Saeed Akhtar; Muhammad Ejaz Khan; Bashar Khan; Javaid Irfanullah; Muhammad Shahzad Afzal; Muhammad Aleem Khan; Muhammad Afzal Nadeem; Mustansar Jehangir; Muhammad Babar Imran
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-29       Impact factor: 9.236

6.  Utility of ⁹⁹mTc-labelled antimicrobial peptide ubiquicidin (29-41) in the diagnosis of diabetic foot infection.

Authors:  Shabana Saeed; Jamal Zafar; Bashar Khan; Ali Akhtar; Sumair Qurieshi; Shazia Fatima; Naseer Ahmad; Javed Irfanullah
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

7.  Antimicrobial peptides as infection imaging agents: better than radiolabeled antibiotics.

Authors:  Muammad Saeed Akhtar; Muhammad Babar Imran; Muhammad Afzal Nadeem; Abubaker Shahid
Journal:  Int J Pept       Date:  2012-05-17

8.  Evaluation of 99mTc-UBI 29-41 scintigraphy for specific detection of experimental Staphylococcus aureus prosthetic joint infections.

Authors:  Laure Sarda-Mantel; Azzam Saleh-Mghir; Mick M Welling; Alain Meulemans; Jean-Marc Vrigneaud; Olivier Raguin; Florence Hervatin; Geneviève Martet; Françoise Chau; Rachida Lebtahi; Dominique Le Guludec
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-03       Impact factor: 10.057

9.  (99m)tc-Ubiquicidin [29-41], a Promising Radiopharmaceutical to Differentiate Orthopedic Implant Infections from Sterile Inflammation.

Authors:  Davood Beiki; Gholamali Yousefi; Babak Fallahi; Mohammad Naghi Tahmasebi; Ali Gholamrezanezhad; Armaghan Fard-Esfahani; Mostafa Erfani; Mohammad Eftekhari
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

10.  Can we produce an image of bacteria with radiopharmaceuticals?

Authors:  A Signore; C D'Alessandria; E Lazzeri; R Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.